An observational study in Asthma Bronchiale, Asthmatic Patients and Asthmatics, sponsored by Schön Klinik Berchtesgadener Land. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-08.
Sponsored by Schön Klinik Berchtesgadener Land · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 385 studies in Asthma with a site in Germany — 20 open to participants now, 29 under way, 7 of them phase 3. Asthma · Germany.
Among the 385 studies in Asthma with a site in Germany, this one is the 34th largest by enrollment of the 46 observational ones that give a count, is one of 13 that started in 2021, is one of 46 observational ones, and was the 370th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →20 of the 385 studies in Asthma with a site in Germany are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Germany, Argentina, France and 7 more countries
Ages 12–17
Kymera Therapeutics, Inc. · Sites in Germany, United States, Poland and 1 more country
Ages 18+
Sanofi · Sites in Germany, United States, Canada and 3 more countries
Ages 6+
Chiesi Farmaceutici S.p.A. · Sites in Germany, Argentina, Bosnia and Herzegovina and 11 more countries
Ages 18–75
Generate Biomedicines · Sites in Germany, United States, Brazil and 18 more countries
Ages 12–80
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
385 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 45 · Phase 2 130 · Phase 3 118 · Phase 4 31
First in 1996; this study’s year is marked. 13 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 62 is below the median of 159 across 1,254 observational studies indexed under Asthma.
Median enrollment 209 across the 338 interventional studies, 239 across the 46 observational. Of the 350 that completed or were terminated, 180 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
331 of 385 have an industry lead sponsor. The 10 most frequent:
Schön Klinik Berchtesgadener Land is the lead sponsor of 51 studies on the registry; 2 are open to participants now.
Schön Klinik Berchtesgadener Land has 1 study filed under Asthma — fewer than ten, so there is no comparison to draw.
9 of the studies in Asthma with a site in Germany that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06052267Phase 3Teva Branded Pharmaceutical Products R&D LLCA Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations | 2026-12-31 |
| NCT06473779Phase 3AstraZenecaOpen-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. | 2027-06-25 |
| NCT05903001RWTH Aachen UniversityDiaphragmatic Function as a Biomarker | 2026-12-30 |
| NCT06317909Fraunhofer-Institute of Toxicology and Experimental MedicineDevelopment of a Novel Non-invasive Inflammometry Following Allergen Challenge in Patients With Mild Allergic Asthma | 2027-03 |
| NCT06572228Regeneron PharmaceuticalsEfficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma | 2027-04-24 |
Add all 9 to your calendar (.ics) → With an account.
Among the 385 studies in Asthma with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study investigates the use of fractional exhaled nitric oxide (FeNO) measurement to monitor non-pharmacological therapy during a three-week inpatient rehabilitation programme for asthma patients. It compares FeNO levels (measured three times a day) with clinical parameters and quality of life to analyse daily fluctuations and the acute effect of exercise training on FeNO levels. As FeNO is a non-invasive biomarker of airway inflammation, this study aims to expand its role in therapy monitoring and explore its application in a rehabilitation setting.
Patients will be recruitet at the pulmonary rehabilitation center at the Schön Klinik Berchtesgadener Land in Schönau am Königssee, Germany
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fractional Exhaled Nitric Oxide (FeNO) at rest
Measurement of FeNo will be done with the Vivatmo Me device (by Bosch Health Care Solutions GmbH)
Time frame: From enrollment to the end of rehabilitation at 3 weeks. Daily measurements at 9AM; 1PM; 5PM
Fractional Exhaled Nitric Oxide (FeNO) before/after exercise
Measurement of FeNo will be done with the Vivatmo Me device (by Bosch Health Care Solutions GmbH)
Time frame: From enrollment to the end of rehabilitation at 3 weeks, FeNO measurements will be done before and after a bicycle endurance training
Asthma control
Assessed by Asthma Control Test (ACT)
Time frame: On admission and discharge from the 3-week rehabilitation programme
Lung function
Forced expiratory flow in 1 second, will be measured by Bodyplethysmography
Time frame: On admission and discharge from the 3-week rehabilitation programme
Eosinophils
Eosinophils will be collected by venous blood sample. Unit: total number of cells per ul blood and percentage
Time frame: On admission and discharge from the 3-week rehabilitation programme
C-reactive protein
C-reactive protein will be collected by venous blood sample. Unit: mg/liter
Time frame: On admission and discharge from the 3-week rehabilitation programme
Immunoglobulin E (IgE)
Immunoglobulin E will be collected by venous blood sample. Unit: ug/liter
Time frame: On admission and discharge from the 3-week rehabilitation programme
6-minute walk test
This test will be performed according to the described standard of the American Thoracic Society and the European Respiratory Society 2014
Time frame: On admission and discharge from the 3-week rehabilitation programme
Plan to share: Yes — The data will be made available upon personal request.
Supporting information: Study protocol, Informed consent form
Time frame: The data will be made available upon personal request.
Access criteria: The data will be made available upon personal request submitting a proposal that describes planned analyses.
No publications or documents are linked to this record.
Ran from May 2021 to primary completion in Dec 2024, 43 months.
Of 366 non-industry observational studies under Asthma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 97. This study's 43 months is above that.
Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Schön Klinik Berchtesgadener Land